桃红四物汤调控EGFR/ERK1/2信号通路抗乳腺癌的保护机制
桃红四物汤(THSWD)在临床用于乳腺癌治疗,但其靶向分子与机制不明。本研究在乳腺癌细胞与小鼠模型中观察到THSWD诱导坏死和/或凋亡、显著抑制细胞迁移,靶蛋白包括EGFR、RAS等,作用与EGFR/ERK1/2信号通路相关,提示其可作为补充治疗进一步研究。
要点
- THSWD可诱导乳腺癌细胞坏死和/或凋亡并显著抑制迁移。
- THSWD抗乳腺癌靶蛋白包括EGFR、RAS等。
- THSWD作用与EGFR/ERK1/2信号通路相关。
核心结论
- THSWD抗乳腺癌的主要作用机制与EGFR/ERK1/2信号通路相关,提示其作为补充治疗值得进一步研究。
研究设计与样本
- 研究在乳腺癌细胞和乳腺癌小鼠模型中开展,采用AO/EB染色、Transwell实验、流式细胞术、免疫荧光等方法。
主要发现
- THSWD诱导乳腺癌细胞坏死和/或凋亡,并显著抑制细胞迁移。
- THSWD抗癌活性靶蛋白包括EGFR、RAS等。
- THSWD治疗乳腺癌与EGFR/ERK1/2信号通路相关。
临床怎么用
- 上述结果为初步机制证据,支持THSWD作为乳腺癌补充治疗进一步研究,尚不能据此形成临床推荐。
局限性
- 原文未报告样本量、具体效应数值与统计学参数,机制结论为初步发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Tao Hong Si Wu Decoction (THSWD), a traditional Chinese herbal medicine, is widely utilized in clinical settings, either alone or in combination with other medications, for the treatment of breast cancer. AIM OF THE STUDY: The specific targeting molecule(s) of THSWD and its associated molecular mechanisms remain unclear. This research aims to elucidate the underlying molecular mechanisms of THSWD in the treatment of breast cancer. MATERIALS AND METHODS: The pharmacological properties of THSWD were investigated in breast cancer cells and tumor tissues using a range of methods including Acridine Orange/Ethidium Bromide (AO/EB) staining, Transwell assay, flow cytometry, immunofluorescence assay, and breast cancer mice models. RESULTS: Our findings demonstrate that THSWD induces necrosis and/or apoptosis in breast cancer cells, while significantly inhibiting cell migration. Target proteins of THSWD in anticancer activity include EGFR, RAS, and others. THSWD treatment for breast cancer is associated with the EGFR/ERK1/2 signaling pathway. CONCLUSION: Our findings offer initial insights into the primary mechanism of action of THSWD in breast cancer treatment, indicating its potential as a complementary therapy deserving further investigation.
引用
- Huang S, Yao D, Shan C, et al. The protective mechanism of Tao Hong Si Wu decoction against breast cancer through regulation of EGFR/ERK1/2 signaling. J Ethnopharmacol. 2024. PMID: 38777083. doi:10.1016/j.jep.2024.118339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。